Release Date: June 5, 2022
Expiration Date: August 30, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 4, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, hematologists, hematologists oncologists, advanced practitioners, and other oncology HCPs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the criteria for MDS diagnosis, as well as available tools for its classification and risk stratification
- Review endpoints utilized in recent clinical trials that have changed treatment of high-risk MDS
- Discuss unmet clinical needs in patients with high-risk MDS and the rationale for emerging therapies and combination strategies in patients with MDS
- Report the efficacy and safety profiles for current and emerging approaches for the care of patients with higher-risk MDS
Naval G. Daver, MD
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Hanmi, Trovagene FATE Therapeutics, Novimmune, Glycomimetics; Consultant: Daichii-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead, Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, Trillium, Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, Agios.
Guillermo Garcia-Manero, MD
Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: BMS, Astex, Novartis, AbbVie, Genentech, APR, Curis, Gilead.
Uma Borate, MD, MS
Clinical Associate Professor
Division of Hematology
The Ohio State University Comprehensive Cancer Center-James
Columbus, OH
Disclosures: Grant/Research Support: AbbVie, Incyte, Jazz, Pfizer; Other: Advisory board: AbbVie, Genentech, Agios, Novartis, Blueprint, Astellas, Takeda.
Jacqueline S. Garcia, MD
Physician
Dana-Farber Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: AbbVie, Genentech, AstraZeneca, Pfizer, Prelude; Consultant: AbbVie, Genentech, Astellas.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
